Vaxcyte’s (PCVX) Overweight Rating Reaffirmed at Cantor Fitzgerald

Cantor Fitzgerald reiterated their overweight rating on shares of Vaxcyte (NASDAQ:PCVXFree Report) in a research report report published on Thursday morning, Benzinga reports.

Separately, Needham & Company LLC reiterated a buy rating and issued a $95.00 target price on shares of Vaxcyte in a report on Thursday.

Get Our Latest Stock Analysis on PCVX

Vaxcyte Trading Up 0.6 %

Shares of PCVX traded up $0.38 on Thursday, reaching $65.57. 333,766 shares of the company’s stock were exchanged, compared to its average volume of 804,928. The business has a 50 day moving average price of $65.84 and a two-hundred day moving average price of $62.80. Vaxcyte has a 12 month low of $44.20 and a 12 month high of $82.04. The stock has a market capitalization of $7.13 billion, a P/E ratio of -15.23 and a beta of 0.94.

Vaxcyte (NASDAQ:PCVXGet Free Report) last released its quarterly earnings data on Wednesday, May 8th. The company reported ($0.85) EPS for the quarter, beating analysts’ consensus estimates of ($1.13) by $0.28. Equities research analysts predict that Vaxcyte will post -3.98 EPS for the current year.

Insider Buying and Selling

In other news, CFO Andrew Guggenhime sold 8,000 shares of the company’s stock in a transaction dated Thursday, April 18th. The shares were sold at an average price of $61.27, for a total value of $490,160.00. Following the sale, the chief financial officer now directly owns 95,679 shares of the company’s stock, valued at approximately $5,862,252.33. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other news, CFO Andrew Guggenhime sold 8,000 shares of the stock in a transaction dated Thursday, April 18th. The shares were sold at an average price of $61.27, for a total value of $490,160.00. Following the transaction, the chief financial officer now directly owns 95,679 shares of the company’s stock, valued at $5,862,252.33. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Grant Pickering sold 15,000 shares of the company’s stock in a transaction dated Tuesday, April 23rd. The shares were sold at an average price of $61.92, for a total transaction of $928,800.00. Following the completion of the transaction, the chief executive officer now owns 477,847 shares in the company, valued at approximately $29,588,286.24. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 63,294 shares of company stock worth $4,254,105. 3.10% of the stock is owned by insiders.

Institutional Investors Weigh In On Vaxcyte

Large investors have recently bought and sold shares of the company. Covestor Ltd lifted its holdings in shares of Vaxcyte by 451.7% during the 1st quarter. Covestor Ltd now owns 1,153 shares of the company’s stock worth $79,000 after acquiring an additional 944 shares during the period. Cercano Management LLC acquired a new stake in shares of Vaxcyte in the 1st quarter valued at $18,591,000. Vanguard Group Inc. increased its stake in shares of Vaxcyte by 15.2% in the 1st quarter. Vanguard Group Inc. now owns 9,737,254 shares of the company’s stock valued at $665,152,000 after purchasing an additional 1,284,883 shares during the last quarter. Westfield Capital Management Co. LP raised its holdings in shares of Vaxcyte by 9.0% during the 1st quarter. Westfield Capital Management Co. LP now owns 1,586,095 shares of the company’s stock worth $108,346,000 after buying an additional 130,502 shares in the last quarter. Finally, ProShare Advisors LLC lifted its position in shares of Vaxcyte by 23.4% during the 1st quarter. ProShare Advisors LLC now owns 26,667 shares of the company’s stock worth $1,822,000 after buying an additional 5,060 shares during the last quarter. 96.78% of the stock is currently owned by institutional investors and hedge funds.

About Vaxcyte

(Get Free Report)

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.

Recommended Stories

Receive News & Ratings for Vaxcyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxcyte and related companies with MarketBeat.com's FREE daily email newsletter.